Skip to main content

Bexion Pharmaceuticals doses first patient in new cancer clinical study

A Northern Kentucky startup developing targeted therapies for cancer has dosed its first patient in a new clinical study being held in Cincinnati.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.